Insulin therapy in obese, non-insulin-dependent diabetes induces improvements in insulin action and secretion that are maintained for two weeks after insulin withdrawal.
about
Differential regulation of two distinct glucose transporter species expressed in 3T3-L1 adipocytes: effect of chronic insulin and tolbutamide treatmentSustained efficacy of insulin pump therapy compared with multiple daily injections in type 2 diabetes: 12-month data from the OpT2mise randomized trialGlucose supply and insulin demand dynamics of antidiabetic agents.Inhibition of obesity-induced hepatic ER stress by early insulin therapy in obese diabetic rats.Effects of current therapeutic interventions on insulin resistance.Reduced capacity and affinity of skeletal muscle for insulin-mediated glucose uptake in noninsulin-dependent diabetic subjects. Effects of insulin therapyEffect of nicotinic acid-induced insulin resistance on pancreatic B cell function in normal and streptozocin-treated baboons.The underuse of insulin therapy in North America.Role of glucose transporters in the cellular insulin resistance of type II non-insulin-dependent diabetes mellitusThe effects of diet and exercise in the treatment of non-insulin dependent diabetes mellitus.When to use insulin in the maturity onset diabeticShort insulin tolerance test can determine the effects of thiazolidinediones treatment in type 2 diabetesSodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitusInsulin pump for type 2 diabetes: use and misuse of continuous subcutaneous insulin infusion in type 2 diabetes.Role of glucotoxicity and lipotoxicity in the pathophysiology of Type 2 diabetes mellitus and emerging treatment strategies.Correction of hyperglycemia with phloridzin restores the glucagon response to glucose in insulin-deficient dogs: implications for human diabetes.Insulin therapy in maturity-onset diabetes.HOMA-beta in the UKPDS and ADOPT. Is the natural history of type 2 diabetes characterised by a progressive and inexorable loss of insulin secretory function? Maybe? Maybe not?Combined insulin-sulfonylurea treatment of type II diabetes.The biochemistry of diabetes.Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats.Insulin resistance in normal rats infused with glucose for 72 h.Treating to target in type 2 diabetes: a case presentation.Molecular Biology as a Tool in the Study of Glucose Transport and Metabolism
P2860
Q28355206-CAC850BC-3BE1-4275-B4CE-69D9ED4B5834Q31043511-63A8F3BD-392C-4923-B2F9-CC9821DF8DE5Q33828255-0F38238F-2157-4D53-A346-5EDEA6E9266CQ34103753-5F00E20D-F26B-4FB4-ACD1-81D580B8D995Q34163110-E4745044-79CD-4F36-BF26-3D9FB4204979Q34182003-3A78A44C-7EEA-45D5-9E22-3AE13CCF1E80Q34184528-A7E175BB-E57F-416F-82C4-D0581377EC23Q34906374-57B1AECE-C048-4AC1-9C57-517BB8D4DE9EQ35588279-75DC0401-17AA-4014-8B8F-4D8B8521AB84Q35954163-534D8794-1CC4-4337-A994-D52B08A1CA6AQ36721908-0C482EE7-AE2B-4CA4-8DFF-E882405AB477Q37065234-79AC5F17-D1B3-48D7-99D9-F896618F23ABQ37139427-A8A62115-DE94-45ED-BCA6-74BFBDF2192EQ37141727-6CCB5E12-EA08-4D17-8A22-AA50EE848E4DQ37577120-7A0624E8-A6B3-4CDC-8CB7-493993D7B9E0Q37650996-A305CF58-DBC1-4BFD-936F-13B109F9F8ABQ37679810-E0C90189-DBA6-49A2-AC6E-5C81A94213E3Q37723462-769A07FD-6EF9-4A61-ACB7-D1DCE6BB600AQ37724497-1DE61B95-3851-443F-8B6E-DE4C780FBA7CQ38688466-01327ACC-9A56-4BC2-B2DA-788DB239F2D4Q39650599-3BA1EE90-D91D-4667-A5F7-4E482F17D2CCQ41015653-6004CFD8-A139-41D7-8073-BFE701C65E61Q42472533-69B8717A-6833-47A9-BABB-F7AB0CD82FBAQ52012845-8346794E-61D5-4848-A20B-E6AFC5587AC2Q58165655-BE69AD09-C596-4BBA-BCCE-D8B573F93BB0
P2860
Insulin therapy in obese, non-insulin-dependent diabetes induces improvements in insulin action and secretion that are maintained for two weeks after insulin withdrawal.
description
1984 nî lūn-bûn
@nan
1984年の論文
@ja
1984年学术文章
@wuu
1984年学术文章
@zh
1984年学术文章
@zh-cn
1984年学术文章
@zh-hans
1984年学术文章
@zh-my
1984年学术文章
@zh-sg
1984年學術文章
@yue
1984年學術文章
@zh-hant
name
Insulin therapy in obese, non- ...... eeks after insulin withdrawal.
@en
Insulin therapy in obese, non- ...... eeks after insulin withdrawal.
@nl
type
label
Insulin therapy in obese, non- ...... eeks after insulin withdrawal.
@en
Insulin therapy in obese, non- ...... eeks after insulin withdrawal.
@nl
prefLabel
Insulin therapy in obese, non- ...... eeks after insulin withdrawal.
@en
Insulin therapy in obese, non- ...... eeks after insulin withdrawal.
@nl
P2093
P356
P1433
P1476
Insulin therapy in obese, non- ...... eeks after insulin withdrawal.
@en
P2093
P304
P356
10.2337/DIAB.33.7.634
P407
P577
1984-07-01T00:00:00Z